Merck buys ArQule and BTK drug for $2.7bnMerck & Co. has announced it is to snap up ArQule for $2.7 billion, just as the US Share XMerck buys ArQule and BTK drug for $2.7bnhttps://pharmaphorum.com/news/merck-buys-arqule-for/
Nine for 2019: how did we do on our predictions, and what does this mean for 2020?Year-ends prompt reflection, both on what’s happened in the last 12 months and on the year ahead. At Share XNine for 2019: how did we do on our predictions, and what does this mean for 2020?https://pharmaphorum.com/views-and-analysis/nine-for-2019-2020/
Novartis to buy The Medicines Company for $9.7bnNovartis is to buy The Medicines Company and its cholesterol-lowering drug for $9.7 billion, confirming press speculation. The Share XNovartis to buy The Medicines Company for $9.7bnhttps://pharmaphorum.com/news/novartis-to-buy-the-medicines-company-for-9-7bn/
Brisk trade in risky three-drug ‘bet’ option after BMS/Celgene mergerBristol-Myers Squibb’s $74 billion merger with Celgene went ahead this week after clearance from US competition regulators, and Share XBrisk trade in risky three-drug ‘bet’ option after BMS/Celgene mergerhttps://pharmaphorum.com/news/celgene-shareholders/
Novartis eyes $5bn The Medicines Company acquisition – reportsNovartis is leading a group of companies that are considering buying US pharma The Medicines Company searching for Share XNovartis eyes $5bn The Medicines Company acquisition – reportshttps://pharmaphorum.com/news/novartis-eyes-5bn-the-medicines-company-acquisition-reports/
$74bn BMS/Celgene merger finally cleared by competition regulatorsBristol-Myers Squibb and Celgene’s merger looks set to close tomorrow after US competition regulators finally gave the $74 Share X$74bn BMS/Celgene merger finally cleared by competition regulatorshttps://pharmaphorum.com/news/74bn-bms-celgene-merger-finally-cleared-by-competition-regulators/
Alkermes bolts on Rodin Therapeutics to bulk up thin pipelineAlkermes has agreed a $950 million deal to acquire Rodin Therapeutics, a US biotech developing drugs for neurodegenerative Share XAlkermes bolts on Rodin Therapeutics to bulk up thin pipelinehttps://pharmaphorum.com/news/alkermes-bolts-on-rodin-therapeutics-to-bulk-up-thin-pipeline/
Roche increases IPF presence with $1.39bn Promedior buyRoche has agreed to buy US biotech Promedior, and a portfolio of drugs including a promising molecule for Share XRoche increases IPF presence with $1.39bn Promedior buyhttps://pharmaphorum.com/news/roche-looks-to-increase-ipf-presence-with-1-39bn-promedior-buy/
Merck builds in CNS diseases with $576m Calporta buyMerck & Co has had mixed fortunes in neurological diseases of late, but remains committed to the category Share XMerck builds in CNS diseases with $576m Calporta buyhttps://pharmaphorum.com/news/merck-builds-in-cns-diseases-with-576m-calporta-buy/
